With a world-class team of urologists, oncologists, and physician-scientists, the Department of Urology at Northwestern Medicine has been at the forefront of clinical and research advancements in urology for more than a century. Northwestern Medicine Urology is committed to providing personalized, integrative, and innovative urologic care and conducting leading-edge research for the prevention, diagnosis and treatment of urologic conditions. In light of this commitment, the Urology Program at Northwestern Memorial Hospital is the highest-ranked program in Illinois and No.11 in the country by U.S. News & World Report, 2021 – 2022 and among the top three NIH-funded urology departments in the nation.
Dr. Nam describes an increase in vasectomies following the Dobbs ruling
July 29th 2024"Compared to the prior years, we found that there was a 150% increase in new vasectomy consults that were completed, and there was a 160% increase in the number of vasectomies that were done," says Catherine S. Nam, MD.
Dr. Meeks highlights the recent innovation in bladder cancer
May 4th 2024"BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer," says Joshua J. Meeks, MD, PhD.
Dr. Patel on a study comparing diagnostic approaches for renal masses
May 3rd 2024Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)."
Dr. Schaeffer looks ahead on what to expect from PSMA-PET in prostate cancer
March 21st 2024"PSMA-PET is a radio nucleotide-based imaging modality that really has changed the landscape of how we initially stage and subsequently follow individuals who have a diagnosis of prostate cancer," says Edward M. Schaeffer, MD, PhD.
Drug extends survival in prostate cancer with genetic mutations
December 8th 2023“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
AI tool predicts survival in patients undergoing RP in the PLCO trial
November 29th 2023"Specifically when we stratified by tertiles, we saw that at 15 years there was a significant difference in cancer-specific survival for those who had a high MMAI score vs lower MMAI scores," says Eric Li, MD.